Inovio, Tripep File for Approval of Hepatitis Vaccine Study
Posted on: Tuesday, 5 December 2006, 12:01 CST
Inovio Biomedical has said that its partner, Tripep AB of Sweden, has filed an application with the Swedish Medical Products Agency, for a phase I study evaluating their hepatitis C vaccine.
The application is designed to permit initial clinical testing of Tripep's proprietary DNA vaccine, ChronVac-C, administered using Inovio's MedPulser DNA Delivery System. This combination is designed to activate a T-cell response capable of clearing hepatitis C virus. Tripep intends to conduct a phase I study in Sweden beginning in early 2007.
"This vaccine trial represents the first study in man of an infectious disease vaccine delivered with electroporation and we are excited about the product's potential," said Avtar Dhillon, Inovio's president and CEO.
Intramuscular delivery of DNA vaccines using Inovio's proprietary electroporation technology has been shown in primate studies to boost the immune response by orders of magnitude over DNA plasmid alone. Plasmid-based vaccines induced higher levels of antibodies and T-cell responses when delivered via electroporation, suggesting the potential to provide better protection from infectious diseases such as HIV and hepatitis C.
Source: Datamonitor
Related Articles
- Inovio Biomedical Expands Electroporation License With IAVI
- Inovio Biomedical Licenses Electroporation Delivery Technology to Leading U.S. Government Contractor, Advanced BioScience Laboratories, Inc.
- Merck's Investigational HIV Vaccine Fails in Study
- Inovio Biomedical's DNA Vaccine Delivery Technology Moves Ahead in Clinical Trial for Hepatitis C
- Inovio Biomedical's DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
- Inovio Biomedical's DNA Delivery Technology for Immunotherapy to Be Presented at Drug Delivery Conference
- Inovio Biomedical DNA Delivery Technology Presented By Wyeth Researcher at Vaccine Conference
- Inovio Biomedical DNA Delivery Technology to Be Presented at the Fifth World Congress on Vaccines By Researcher From Merck & Co., Inc.
- Inovio's License of Electroporation Intellectual Property Includes Skin Delivery Technology Used in Anthrax Collaboration
- PowderMed: Bush Pushes for Mass-Produced Avian Flu Vaccine; DNA-Based Vaccine Offers Hope for Rapid Response
 |
 |
User Comments (0)
RSS Feeds